Eisai
Eisai cancer drug performs in sarcoma disease
February 26, 2015Sales and Marketing Cancer, Eisai, Halaven, eribulin, sarcoma, tumour
Eisai’s cancer drug Halaven met its primary endpoint and demonstrated overall survival benefit in two distinct solid tumour types in …
FDA approves Eisai thyroid drug, fast-tracks Novartis heart pill
February 16, 2015Sales and Marketing Eisai, FDA, LCZ696, Lenvima, Novartis, heart, lenvatinib, thyroid
The FDA has approved Eisai’s thyroid cancer drug Lenvima and also granted Novartis heart pill LCZ696 a priority review. Lenvima …
Eisai: Fycompa decision ‘deeply regrettable’
November 11, 2014Research and Development, Sales and Marketing Eisai, Fycompa, Germany, epilepsy, gba, perampanel
Eisai has lashed out at a major German health assessment body, calling its stance on first-in-class epilepsy treatment Fycompa ‘deeply …
FDA approves Eisai’s chemo side-effects drug
October 15, 2014Research and Development, Sales and Marketing Eisai, FDA, Helsinn, akynzeo, chemotherapy, cinv
Eisai and Helsinn Healthcare’s Akynzeo (netupitant/palonosetron) has received FDA approval for the treatment of chemotherapy-induced nausea and vomiting (CINV). CINV …
ABPI and BIA establish new manufacturing partnership
September 23, 2014Manufacturing and Production, Sales and Marketing ABPI, Actavis, AstraZeneca, BIA, Eisai, Fujifilm Diosynth Biotechnologies, GlaxoSmithKline, Knowledge Transfer Network (KTN), Oxford BioMedica, Pfizer, Whitehead, bates, mmip
The ABPI and the Bioindustry Association (BIA) have jointly established a new Medicines Manufacturing Industry Partnership (MMIP) to boost medicines …
Alzheimer’s disease: pharma’s greatest challenge
April 4, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AD, Alzheimer's, Alzheimer’s, Eisai, Lunt, Pfizer, galantamine, karran, priddy
Like it or not, we are all becoming increasingly prone to a currently incurable and debilitating disease, that places an …
Alzheimer’s tie-up for Eisai and Biogen
March 6, 2014Research and Development, Sales and Marketing Alzheimer's, BAN2401, Biogen IDEC, E2609, Eisai
Eisai and Biogen Idec have joined forces to look for new Alzheimer’s treatments, developing and commercialising two of the Japanese …
Eisai reorganises R&D
December 2, 2013Research and Development, Sales and Marketing Eisai, R&D, cfu, epcs, pcu, reorganisation
Tokyo-based Eisai is to axe 130 jobs in Europe and the US as part of an attempt to shake up …
Eisai signs tropical disease deal
November 12, 2013Research and Development, Sales and Marketing Disease, Eisai, Japan, broad, ntd, tropical
Eisai has become the latest pharma firm to partner with the US-based Broad Institute to pool expertise and come up …
Eisai: reform NICE or we’ll pull out of the UK
October 21, 2013Research and Development, Sales and Marketing Eisai, Hatfield, Hunt, NICE
Eisai has criticised NICE for being too narrow minded on assessing new drugs, and has warned it may pull its …
Eisai backs disease fund
July 12, 2013Research and Development, Sales and Marketing Eisai, Japan, TB, partnership
A leading Japanese pharma group says that the sector should see investment in fighting diseases of the developing world as …
Eisai’s £8 million UK expansion
June 17, 2013Manufacturing and Production Eisai
Eisai has decided to invest further into its Hertfordshire production plant in the UK towards the creation of an additional …
Eisai appoints chief clinical officer
April 12, 2013Manufacturing and Production, Research and Development, Sales and Marketing Eisai
Eisai has announced the immediate appointment of Lynn Kramer to the newly created position of chief clinical officer of Eisai …
Pharma manufacturing news in brief
March 11, 2013Business Services, Manufacturing and Production Actavis, DSM, Eisai, J&J, JJ, Marken, SAFC, Sagent Pharma
Actavis revises supply deal with Sagent, facility updates from Marken and SAFC, a supply deal for DSM plus another J&J …
Eisai cancer drug fails
January 14, 2013Research and Development, Sales and Marketing Cancer, Eisai, Morphotek, farletuzumab
Eisai’s investigational oncology treatment farletuzumab has failed to reach its primary endpoint in a late-stage trial. Farletuzumab (MORAb-003) did not …
Latest content
Five Facts about cardiovascular disease
